Current status of targeted therapy in metastatic transitional cell carcinoma of the bladder

Area of Science:

• Oncology
• Genitourinary Cancer Research
• Molecular Biology

Background:

• Urothelial bladder cancer is a significant genitourinary (GU) malignancy, ranking second in incidence and posing substantial treatment challenges due to high mortality and cost.
• Therapeutic progress for bladder cancer has lagged behind other GU cancers, despite a long-standing understanding of its underlying genetic landscape.
• Numerous molecular targets have been identified based on this genetic knowledge, paving the way for novel therapeutic strategies.

Purpose of the Study:

• To review the current understanding of urothelial bladder cancer biology concerning target identification.
• To provide a comprehensive overview of clinical trial data evaluating therapeutic strategies targeting identified molecular pathways.
• To bridge the gap between fundamental bladder cancer biology and clinical application of novel treatments.

Main Methods:

• Systematic literature review of peer-reviewed articles on urothelial bladder cancer biology and molecular targets.
• Analysis of published clinical trial data investigating targeted therapies for bladder cancer.
• Synthesis of information on genetic drivers, identified targets, and outcomes of clinical investigations.

Main Results:

• Established knowledge of bladder cancer genetics has facilitated the identification of multiple therapeutic targets.
• Clinical trials have explored various targeted therapeutic strategies, with data indicating a spectrum of efficacy and challenges.
• The review highlights specific biological pathways and targets that are under investigation for improved bladder cancer treatment.

Conclusions:

• Despite identified targets, the translation of biological insights into improved clinical outcomes for urothelial bladder cancer remains an ongoing challenge.
• Further research and clinical trials are necessary to fully exploit identified targets and develop more effective treatment regimens.
• A deeper understanding of bladder cancer biology continues to inform the development of precision medicine approaches for this disease.